MedTrace Logo

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

NCT07357766 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1400

Last updated 2026-02-25

No results posted yet for this study

Summary

This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.

Conditions

Interventions

DRUG

Cagrisema

Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.

DRUG

Placebo CagriSema

Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency dept. 2834 · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-22
Primary Completion
2027-11-29
Completion
2028-01-17
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Denmark
  • Greece
  • Hungary
  • Malaysia
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • South Africa
  • Switzerland
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07357766 on ClinicalTrials.gov